:quality(80)/s3.amazonaws.com/arc-authors/morningstar/27df33e4-c5eb-4dc8-805e-babc7c688b65.jpg)
DaVita's Outlook Is Improving Despite Obesity Drug Expansion
After selling the DaVita Medical Group in 2019, DaVita focuses almost exclusively on providing services to end-stage renal disease, or ESRD, patients primarily in the United States with an expanding international footprint. Over several decades, DaVita has built the largest network of dialysis clinics in the U.S., and although COVID-19-related mortality and labor pressures cut into DaVita's profits in recent years, we see brighter days ahead for DaVita, despite some challenges emerging on the obesity drug front.